


Three men with pain and difficulty urinating
Dr Scott Dryden-Peterson
Isaac Nkele



Continuing Medical Education Announcement

Harvard Medical School

RSS 3081: Monthly BOTSOGO Tumor Board; 2017-2018 Academic Year

Today's Objectives:

- Describe the need for timely cancer case presentation and referral to treatment
- Formulate a multi-disciplinary plan for the care of common and complex oncologic cases
- Adopt successful, sustainable strategies to mitigate barriers to quality cancer care common in resource constrained environments

Target Audience:

Oncologists, internists, surgeons, radiation oncologists, infectious disease specialists, nurses, physicists, therapists, technicians, research staff, administrators, policy makers.



Financial Relationships

The following planners, speakers, and content reviewers, on behalf of themselves and their spouse or partner, have reported financial relationships with an entity producing, marketing, re-selling, or distributing health care goods or services (relevant to the content of the activity) consumed by, or used on, patients:

Name	Role	Type of Financial Relationship

All other individuals including course directors, planners, reviewers, faculty, staff, etc., who are in a position to control the content of this educational activity have reported no financial relationships related to the content of this activity



Statements

Accreditation Statement

The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians

Credit Designation Statement

The Harvard Medical School designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity

This activity meets the criteria of the Massachusetts Board of Registration in Medicine for 1.0 credits of Risk Management Study

Disclosure Statement

In accord with the disclosure policy of the Medical School as well as standards set forth by the Accreditation Council for Continuing Medical Education, course planners, speakers, and content reviewers have been asked to disclose any relevant relationship they, or their spouse or partner, have to companies producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients.



Claim your CME credits!

- To claim your CME credit for attendance at this session of the BOTSOGO Tumor Board, please fill out our survey after the Tumor Board.
- You can do this at your convenience on your personal or work computer by navigating to www.botsogo.org
 - Click “What We Do”
 - Click “Tumor Board”
 - Click the link under the section “Continuing Education Credits,” and complete and submit the survey
- Or follow the link that was emailed to our MGH BOTSOGO email list: www.tinyurl.com/tumourboard







Potlako Team



Men and diagnosis/treatment for cancer in Botswana:

Decreased access to diagnosis/treatment

- Men present at PMH/NRH/GPH/BPH with more advanced stage cancer than women
- Early Potlako data: men 4-times less likely to receive any cancer specific therapy, majority of men NOT treated for their cancer before dying
- Leading untreated cancers in men are prostate and esophageal cancer



Today's discussion:

Goal to start to define a diagnostic approach for patients with suspected prostate cancer

Key questions:

- Who in health system does prostate exam currently and who should be doing exams?
- What is the yield/utility of ultrasound?
- Is there a PSA cut-off where biopsy should always be attempted?
- Which patients should be referred to urology?
- When is treatment indicated for presumptive diagnosis without biopsy and/or PSA?





Case 1—73yoM HIV- with fatigue and abdominal pain:

“Difficulty urinating, dysuria, and abdominal pain”

- Previously seen at 4 different facilities: primary clinic, PMH, BLH, and GPH
- Enrolled in Potlako at SLH/SOPD in mid-March 2017, felt to be low probability of cancer (BPH most likely)
- Hematuria and catheter placed, PSA drawn
- Symptomatically improved for 2-3mo, going monthly to try to get PSA results, not available
- Potlako team asked for help from NHL/UB pathology, ‘will get back to you’, team reviewing for results in IPMS frequently



Case 1—73yoM HIV- with fatigue and abdominal pain:

Clinical decline

- July 2017, gasping for breath presented to BLH, pleural and pericardial effusion diagnosed
- Admitted to PMH and catheterized with improvement in symptoms and able to return home, but further details of treatments uncertain to patient
- Still no PSA results



Case 1—73yoM HIV- with fatigue and abdominal pain:

In person visit with Potlako coordinator at SLH, Sept 2017

- Review of records with 2 ultrasounds readings suspicious for prostate cancer
- Patient with leg swelling, occasional SOB, variable urine stream that improves after catheterization but doesn't last
- Record of PSA being drawn but no results
- Current referral for cardiology given 'water around liver'
- Never referred to urology, because awaiting PSA result
- Patient frustrated w/ health system
- Potlako coordinator booked with urology



Case 1—73yoM HIV- with fatigue and abdominal pain:

PMH Urology

- Seen at PMH urology and CT ordered, 1mo wait
- Potlako team found PSA result, >150 ng/mL
- Reviewed again in urology, but biopsy needles out of stock
- Patient requested by urology to call PMH minor theatre regularly to see if needles have come in stock
- Patient and Potlako team have called this week, still no needles





Case 2—76yoM HIV- with inguinal swelling:

“Long standing inguinal swelling and periodic pain”

- Symptoms started about 10yrs ago
- No cutaneous sores
- Seen at local clinic and SLH, biopsy planned but told possibility that ‘could not wake up’ so refused
- Getting worse
- Enrolled in Potlako in April 2017

SLH evaluation- May 2017

- Ultrasound with ‘fingerlike projection in bladder’
- PSA drawn



Case 2—76yoM HIV- with inguinal swelling:

Awaiting PSA results

- Returned 5 times to get PSA results at SLH
- Referred to PMH urology and traveled to Gaborone, but turned away at reception as no PSA results
- Potlako coordinator learnt that contract for PSA testing lapsed between NHL and some private LAB for PSA reagents, NHL seeking new tender/contract
- Potlako discussed with urology, need to get a new PSA drawn



Case 2—76yoM HIV- with inguinal swelling:

New PSA draw- Sept 2017

- Patient returned to SLH to have new PSA draw, but turned away by security as OPD cards said should be drawn in October
- Potlako advised to return and explain why needed draw
- PSA returned in early Oct 2017 at 54.34 ng/mL in IPMS





Case 3—58yoM HIV- with back pain:

“Waist ache and bone aches all over body”

- Symptoms started in Dec 2016
- Seen at local clinic
- Seen by private doctor who obtained X-ray
- Admitted to SLH MSW with bony lesions, late Jan 2017
- Ultrasound with prostate mass, **no biopsy or PSA done**

PMH Oncology

- Seen during SLH admission, referred for RT
- Started RT at GPH in early April 2017





Summary of today's discussion:

Goal: Start to define a diagnostic approach for patients with suspected prostate cancer.

Key questions:

- Who in health system does prostate exam currently and who should be doing exams?
We confirmed that all doctors in Botswana have received training in prostate exam; discussion revealed that not all doctors actually perform this and may have limited experience in identifying nodules. Further dedicated training may be warranted.
- What is the yield/utility of ultrasound?
Transrectal ultrasound is preferable to abdominal ultrasound but neither are ideal diagnostic tools, and do not take the place of a digital rectal exam.



Today's discussion:

Key questions, continued:

- Is there a PSA cut-off where biopsy should always be attempted?

Discussion yielded no clear cutoff PSA; PSA over 20 rarely seen in settings of prostatitis (or other non-cancer diagnoses) and PSA over 10-20 should be followed by biopsy when available.

- When is treatment indicated for presumptive diagnosis without biopsy and/or PSA?

PSA over 100 may warrant treatment even without biopsy; this is a topic that will benefit from continued discussion.

